Assessment of Influential Variables in the Pricing of Locally Manufactured Pharmaceuticals: Current Challenging Situation in Iran.

Conflict of interest Government policy Influential variables Lack of transparency Pharmaceutical pricing

Journal

Iranian journal of pharmaceutical research : IJPR
ISSN: 1735-0328
Titre abrégé: Iran J Pharm Res
Pays: Netherlands
ID NLM: 101208407

Informations de publication

Date de publication:
2021
Historique:
entrez: 17 8 2021
pubmed: 18 8 2021
medline: 18 8 2021
Statut: ppublish

Résumé

The lack of transparency and predictability seems to remain one of the major complaints in the pharmaceutical pricing procedure in Iran, but there is not enough official evidence to support it. The main objective of this study was to identify influential variables officially or unofficially influencing the pharmaceuticals pricing in Iran and also clarifying the degree of importance of each variable from the viewpoints of two groups: the pricing Commission members (owners of pricing procedure) and other stakeholders in the pharmaceutical sector. Semi-structured interviews with experts were performed to extract the influential variables. A Likert scale questionnaire was designed based on extracted variables and used in above-mentioned two groups of experts. The validity and reliability of the questionnaire were assessed before use. About 68 influential variables were extracted which classified into eight categories or domains. Less than 50% of extracted influential variables on pharmaceutical pricing have been mentioned in Iran pricing regulations. There were statistically significant differences between the two group's viewpoints in terms of importance and effect of some variables on pricing procedure. Conflict of interest, lack of transparency and a sound framework were found as the main problems in Iran pharmaceutical pricing procedure and may lead to "case-by-case" decision making. As such, the output of the pricing commission is not transparent and predictable for its beneficiaries.

Identifiants

pubmed: 34400958
doi: 10.22037/ijpr.2020.112288.13662
pmc: PMC8170750
doi:

Types de publication

Journal Article

Langues

eng

Pagination

283-295

Références

BMJ. 2001 Sep 29;323(7315):743-5
pubmed: 11576985
Int J Health Policy Manag. 2017 Sep 12;7(5):412-420
pubmed: 29764105
J Res Pharm Pract. 2016 Jul-Sep;5(3):155-61
pubmed: 27512704
Eur Respir J. 2002 Mar;19(3):499-503
pubmed: 11936529
Intractable Rare Dis Res. 2014 Feb;3(1):1-7
pubmed: 25343119
Iran J Pharm Res. 2017 Winter;16(1):1-7
pubmed: 28496457
Lancet. 2017 Dec 16;390(10113):2606
pubmed: 29256396
Daru. 2013 Jun 28;21(1):52
pubmed: 23805853
Res Nurs Health. 2007 Aug;30(4):459-67
pubmed: 17654487
J Adv Nurs. 2016 Dec;72(12):2954-2965
pubmed: 27221824
Res Nurs Health. 2006 Oct;29(5):489-97
pubmed: 16977646
Public Health. 2015 May;129(5):444-52
pubmed: 25769347
Psychol Bull. 1968 Oct;70(4):213-20
pubmed: 19673146
Nurs Res. 1986 Nov-Dec;35(6):382-5
pubmed: 3640358

Auteurs

Nikinaz Ashrafi Shahmirzadi (N)

Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Pharmaceutical Management and Economics Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Akbar Abdollahiasl (A)

Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Pharmaceutical Management and Economics Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Abbas Kebriaeezadeh (A)

Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Pharmaceutical Management and Economics Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Classifications MeSH